BNTC (30) VOGX (45) FULC (34) ENTA (20) ⌘ Pro Terminal →

Opus Genetics Inc. (IRD) — RQD Stock Rating Cockpit

$3.65 -0.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.64

Opus Genetics Inc. (IRD) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $303.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IRD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IRD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Opus Genetics Inc. (NASDAQ: IRD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $3.65 (-0.81% 1D, market cap $303.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IRD ranks #964 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IRD compare to BNTC and VOGX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRD carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BNTC (Benitec Biopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $308.1M) and VOGX (Vogenx Inc) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $295.9M). Among the 5-stock peer group, IRD leads on earnings multiple (N/A) while IRD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IRD?

▼

Per IRD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001228627), Opus Genetics Inc. generated $14.2M in revenue (+29.1% YoY), -$49.6M in net income, and -$35.3M in free cash flow against $50.2M in total assets and $1.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.64 (-0.34%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-15.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (23/100 Composite)

🔍 WHY IRD SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (35% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (30% of score)

FRED Regime × Technicals: 36% of 52W Range • RSI-14 at 39.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.64-17.7% Next Q

Q2 (-2Q)

Grade E$3.82-13.1% Next Q

Q3 (-1Q)

Grade E$3.32+9.9% Next Q

Current

Grade E$3.65-11.1% Hist 90D α

Trajectory: E (31) → E (23)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IRD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IRD currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.46) and Max Pain ($3.83) forces dealer call-delta covering toward $7.42.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IRD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 23%NO 77%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

39.330 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE36% OF RANGE

L: $2$3.65H: $7

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 1 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on IRD

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-35.0% ROIC with 42.0% gross margin and -11.61% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 0.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (23)

7/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like IRD

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IRD)

✓Walkthrough of IRD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IRD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.08%📐 HORIZONTAL RANGE

2026-11-02O $3.68H $3.68L $3.65C $3.65VOL 709.6K

RES: $8.45SUP: $3.19SMA50: $4.46SMA200: $4.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRD Butterfly Map → + Track IRD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +29.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IRD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IRD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRD)

Health Care Rank #964 of 1016 ⚔️ BNTC vs IRD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRD vs. BNTC, VOGX, FULC, ENTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Opus Genetics Inc. (IRD) ranks #964 by composite RQD confidence (23/100, grade E) and #517 by equity capitalization ($303.7M). Within this direct 5-issuer industry benchmark cohort, IRD leads on earnings valuation at N/A trailing P/E, while IRD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with IRD at 23/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IRD ACTIVE Opus Genetics Inc.	E	23/100	—	—	-35.0%	-0.81%	$303.7M	Benchmark Subject
BNTC Benitec Biopharma Inc.	E	30/100	—	—	-35.0%	+0.34%	$308.1M	/bntc-vs-ird →
VOGX Vogenx Inc	D	45/100	—	—	—	+5.29%	$295.9M	/vogx-vs-ird →
FULC Fulcrum Therapeutics Inc.	E	34/100	—	—	-35.0%	+0.53%	$288.0M	/fulc-vs-ird →
ENTA Enanta Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	-3.46%	$324.7M	/enta-vs-ird →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001228627

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Opus Genetics Inc. (IRD) reported GAAP revenue of $14.2M (+29.1% vs. FY2024 revenue of $11.0M , and -25.5% cumulative change since FY2023) , GAAP net income of -$49.6M, operating cash flow of -$35.3M, and free cash flow of -$35.3M (-37.8% YoY). On the balance sheet, IRD closed FY2025 with $50.2M in total assets against $1.1M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$14.2M	-$49.6M	-$35.3M	-$35.3M	$50.2M	$1.1M
FY2024 (FY)	2024-12-31	$11.0M	-$57.5M	-$25.6M	-$25.6M	$36.9M	$0
FY2023 (FY)	2023-12-31	$19.0M	-$10.0M	-$1.1M	-$1.1M	—	—

3. IRD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IRD compare to BNTC and VOGX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IRD?

Where is IRD trading relative to its 50-day, 200-day, and 52-week technical levels?

IRD last traded at $3.65 (-0.81% on volume of 709,609 shares), positioning the stock -18.16% below its 50-day simple moving average ($4.46) and -12.89% below its 200-day simple moving average ($4.19). Across its 52-week range of $1.70 to $7.07, IRD sits at the 36.3% percentile with a 14-day RSI of 39.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.19 to $4.11).

IRD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell IRD stock right now?

Opus Genetics Inc. (IRD) currently earns a Roarable Rating of E (Strong Sell — SELL) with 23/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is IRD's 12-month price target and RQD AI Jury consensus?

IRD's 12-month base price target is $3.08 (range $2.4 to $7.42), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: IRD RQD Cockpit IRD 12M Forecast IRD Earnings & Move IRD Dividends & DRIP IRD Insiders & 13F IRD Whale Options IRD Profit Sankey IRD News & Why